another point - these more specific immunocytokines, (which some posters here refer to as "the fusion proteins"), do not obsolesce bavituximab. They're seperate and different entities with specific functions. Seeing them as "better bavi" or "super-charged" bavi is not completely accurate. Today's bavi IMO (and later possibly the betabodies and double B2GPI) will always be necessary to break to cycle of increasing (overwhelming) apoptotic debris of HIV and cancer.
Entdoc, Bavi & FH-Bavi both require B2GP1 to bind to PS. PGN632 (DukeHIV/Genentech-Imaging) is B2GP1-Independent, as are next-gen. Betabodies…
• PGN635 is Fully-Human Bavituximab=1N11=AT004 (B2GPI-depen.); Genentech studying 89Zr-PGN635 as a Tumor Imaging Agent, “indep. of cancer type” • PGN632 is the Duke-PPHM-HIV candidate=11.31=AT005 (B2GPI-indep.); also being studied by PPHM+LSU vs. Ocular Herpes (Acute HSV-1 Keratitis), see http://tinyurl.com/cax9a4p • PGN650 is a human F(ab’)2 fragment that targets PS expression (1st ref’d in AACR’12 #2452) – see http://tinyurl.com/76nqqkm . 124I-PGN650 is Peregrine’s PS-Imaging candidate, whose IND clinical filing was announced 4-3-12, and whose n=12 trial started 6-2012. - - - - - - - - - Note: PGN632 (Duke/HIV preclin’s) binds to PS indep. of B2-glycoprotein I (B2GPI), unlike Bavi & FH-Bavituximab(PGN635) which depend on B2GPI as a binding intermediary.
= = = = = = = = PS is immunosuppressive PS is exploited by genetically diverse pathogens PS is a valid therapeutic target 3 articles by Peter M. Henson (Natl-Jewish/Denver) about the immunosuppressive effects of exposed Phosphatidylserine (PS): • 2-2005: “Interaction between PS & PS Receptor Inhibits Immune Responses In Vivo”, Peter Hoffmann http://www.jimmunol.org/cgi/content/full/174/3/1393 • 1-2002: ”PS-Dep. Ingestion of Apoptotic Cells Promotes TGF-B1 Secretion & Resolution of Inflammation”, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC150814 • 2-1998: ”Macrophages That Have Ingested Apoptotic Cells In Vitro Inhibit Pro-Inflammatory Cytokine Production…” http://www.jci.org/articles/view/1112/files/pdf Peregrine’s Bavituximab generates full immune response against cancer by reversing the inhibitory effect of PS on dendritic cells (DC)…
10-2012 Thorpe Diagram of Bavi-PGN635-PGN650 mabs – from SITC Annual Meeting, Bethesda MD:
News 
Market Data 
Discover 
